Home/Biosimilar Atlas/Companies/Daiichi Sankyo

Daiichi Sankyo

Biosimilar developer, Japan. 1 development product across 1 molecule: adalimumab.

First approval in the Atlas: Jan 2021, Adalimumab BS Daiichi Sankyo, adalimumab (PMDA)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved1
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product1 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AdalimumabAdalimumab BS Daiichi Sankyo···Jan 2021···1/7

Month shown is the first approval or registration of that product in that market.

Also holds or markets

Products developed by another company for which Daiichi Sankyo is the licence holder or applicant in one or more markets.

MoleculeBrandMarketHolder or applicantApprovedDeveloper
TrastuzumabTrastuzumab BS Daiichi SankyoPMDADaiichi SankyoSep 2018Amgen

Companies on the same molecules

Developers whose portfolios overlap most with Daiichi Sankyo, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

AlvotechOne shared molecule: adalimumab5 molecules in its portfolioAmgenOne shared molecule: adalimumab8 molecules in its portfolioBoehringer IngelheimOne shared molecule: adalimumab1 molecule in its portfolioCelltrionOne shared molecule: adalimumab10 molecules in its portfolioCoherus BioSciencesOne shared molecule: adalimumab2 molecules in its portfolioEnzene BiosciencesOne shared molecule: adalimumab6 molecules in its portfolio

Chronology

Compare Daiichi Sankyo with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.